Refractory Angina Clinical Trial
Official title:
Cardiac Rehabilitation in Patients With Refractory Angina
Verified date | March 2020 |
Source | Hospital Israelita Albert Einstein |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and feasibility of cardiovascular rehabilitation in Patients with refractory angina, evaluate the effect of cardiovascular rehabilitation in patients with angina Refractory, by maximal oxygen consumption (VO2max) and global myocardial ischemic load by Stress Echocardiography; To evaluate the presence of myocardial injury, caused by physical stress, through ultra-sensitive troponin after sessions of aerobic physical activity, evaluating the behavior during the training period; To evaluate the effect of rehabilitation on the modulation of sympathetic activity and inflammation, muscular blood flow and lipid metabolism; To evaluate of the effect of rehabilitation on ventricular function through Stress echocardiography; Detection of ischemic episodes and arrhythmias identified during the Rehabilitation sessions through external cardiac monitoring (telemetry); Evaluate the quality of life assessment through the SF-36 questionnaire, Canadian Cardiovascular Society, the number of symptomatic episodes of ischemia, daily sublingual nitrate intake.
Status | Completed |
Enrollment | 72 |
Est. completion date | February 1, 2022 |
Est. primary completion date | July 28, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years to 75 Years |
Eligibility | Group 1 and 2 Inclusion Criteria: - Stable angina functional class II to IV according to the classification of Canadian Cardiovascular Society (CCS) 39, or limiting angina in Perception of the patient; - Documented myocardial ischemia by imaging method; - Patients not eligible for myocardial revascularization procedures surgical conventional, due to the unfavorable anatomy; - Signature of the Free and Informed Consent Form. Exclusion Criteria: - Patients with definitive pacemaker or implantable cardioverter defibrillator (ICD); - Patients with non-sinus heart rhythm; - Patients with complete intraventricular block; - Acute coronary syndrome (myocardial infarction or unstable angina) or previous procedures for myocardial revascularization (angioplasty / surgery) less than 3 months; - Functional impossibility (orthopedic, rheumatic, neurological, or otherwise) or social for participation in the Rehabilitation Program; - Classification of risk for American Heart Association class D physical training (unstable ischemia, stenosis or severe or symptomatic valve insufficiency, congenital heart disease, decompensated heart failure, uncontrolled arrhythmias and other conditions that may be aggravated by exercise). Group 3 Inclusion Criteria: - Patients with coronary insufficiency without angina; - Signature of the Free and Informed Consent Form. Group 4 Inclusion Criteria: - Signature of the Free and Informed Consent Form; - Healthy; - Non-smokers; - Sedentary |
Country | Name | City | State |
---|---|---|---|
Brazil | Instituto Israelita de Ensino e Pesquisa Albert Einstein 's (IIEP) | São Paulo |
Lead Sponsor | Collaborator |
---|---|
Hospital Israelita Albert Einstein | Fundação de Amparo à Pesquisa do Estado de São Paulo, Instituto do Coracao |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiovascular rehabilitation in patients with refractory angina is safe; | Evaluated number of patients who have any kind of cardiovascular event during rehabilitation, as well as number of sore throat during the sessions. | 3 months of rehabilitation | |
Primary | Cardiovascular rehabilitation in patients with refractory angina is efficient; | Evaluated number of sore throat during the sessions. | 3 months of rehabilitation | |
Primary | Improve the maximal oxygen consumption | Improvement of Maximal oxygen uptake (VO2max) | 3 months of rehabilitation | |
Primary | Improve the global myocardial ischemic load | Reduction of myocardial ischemia, evidenced by improvement of the standard by effort echocardiography | 3 months of rehabilitation | |
Secondary | Reduction of myocardial injury caused by physical stress | Improves levels of Troponin-T after 1 exercise session at the initial moment of the Protocol and after 3 months. | 3 months of rehabilitation | |
Secondary | Rehabilitation will modulate sympathetic activity | Decreased sympathetic nerve activity measured by the amount of shots in his microneurography | 3 months of rehabilitation | |
Secondary | Improvement of ventricular function | Improvement of ventricular function through stress echocardiography in patients undergoing rehabilitation | 3 months of rehabilitation | |
Secondary | Improvement of the quality of life | Improvement of the quality of life measured through the SF-36 questionnaire. | 3 months of rehabilitation | |
Secondary | Rehabilitation will increase muscle blood flow | Increase peripheral muscle blood flow measured by plethysmography. | 3 months of rehabilitation | |
Secondary | Reduction in the number of symptomatic episodes of ischemia | Reduction in the number of episodes of ischemia, reduction of daily sublingual nitrate intake. | 3 months of rehabilitation | |
Secondary | Reduction of the daily consumption of sublingual nitrate | Reduction of daily sublingual nitrate intake. | 3 months of rehabilitation | |
Secondary | Improve the functional class of Refractory Angina | Improve the functional class decrease of angina (according to Canadian Cardiovascular Society classification) | 3 months of rehabilitation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01205893 -
Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA
|
Phase 2 | |
Suspended |
NCT04306237 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
|
Phase 2 | |
Recruiting |
NCT04892537 -
Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance
|
N/A | |
Completed |
NCT00694642 -
Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis
|
Phase 1/Phase 2 | |
Suspended |
NCT00820586 -
Intramyocardial Delivery of Autologous Bone Marrow
|
Phase 2 | |
Recruiting |
NCT04368819 -
Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms
|
Phase 2/Phase 3 | |
Recruiting |
NCT05711849 -
Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina
|
Phase 2 | |
Recruiting |
NCT03455725 -
CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial
|
N/A | |
Completed |
NCT01966042 -
Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina
|
Phase 2 | |
Recruiting |
NCT03991871 -
HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study
|
N/A | |
Recruiting |
NCT05102019 -
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
|
N/A | |
Completed |
NCT01796912 -
Lipoprotein Apheresis in Refractory Angina Study
|
N/A | |
Completed |
NCT03350737 -
Coronary Arteriogenetic Heparinized Exercise
|
N/A | |
Recruiting |
NCT01566175 -
Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization
|
N/A | |
Recruiting |
NCT05492110 -
Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.
|
N/A | |
Recruiting |
NCT04606459 -
COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina
|
N/A |